Sitryx Therapeutics Limited is an immunometabolism company focused on applying breaking science relating to the manipulation of metabolism and metabolic reprogramming to develop disease modifying therapeutics targeting:

• Immuno-oncology: limiting the growth of cancer cells by enhancing anti-cancer immune responses and/or recruiting tumour metabolic activity
• Immuno-inflammation: switching immune cell activity from a pathogenic to a homeostatic state to treat inflammatory and autoimmune disorders

Sitryx recently signed an exclusive global licensing and research collaboration with Eli Lilly and Company to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation. Sitryx received an upfront payment of $50 million for this 5-year collaboration and will study up to four novel preclinical targets identified by Sitryx.